

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LIFETECH SCIENTIFIC CORPORATION**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### **CHANGE OF SUBSTANTIAL SHAREHOLDER**

This announcement is made by the board (the “**Board**”) of directors of LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The Company received notice from the Medtronic group (“**Medtronic**”) that on 5 May 2018, Medtronic had entered into a definitive agreement with China Everbright Limited (“**CEL**”, stock code: 165.HK) and another investor to dispose (i) 22.4% equity interests in the Company to CEL and (ii) the rest of Medtronic’s minority equity interests in the Company to such other investor (the “**Transaction**”). Following completion of the Transaction, Medtronic will cease to have any interests in shares of the Company and cease to be a substantial shareholder.

Upon the completion of transaction, the Company will continue to maintain the strategic cooperation with Medtronic on HeartTone<sup>R</sup> pacemaker. Furthermore, both Medtronic and the Company will look for future opportunities to expand the strategic collaboration.

The Group is a leading developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. On the other hand, CEL has investments in healthcare companies through the funds under its management in the area of pharmaceutical, IVD, medical devices, healthcare services and senior care in both China and globally. The Board is of the view that the resources of CEL will fully support the sustainable development of the Group.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Chairman, Chief Executive Officer  
and Executive Director*

Hong Kong, 6 May 2018

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. ZHANG Deyuan and Mr. LIU Jianxiong being executive Directors; Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.*